Hussain Sohail Rangwala

Hussain Sohail Rangwala

Auto-generated profile, based on publicly available information

Hussain Sohail Rangwala

Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
HFHareer Fatima
Hareer Fatima
HRHussain Sohail Rangwala
Hussain Sohail Rangwala
MMMuhammad Saqlain Mustafa
Muhammad Saqlain Mustafa
MSMuhammad Ashir Shafique
Muhammad Ashir Shafique
SASyed Raza Abbas
Syed Raza Abbas
AAAinan Arshad
Ainan Arshad
Introduction: Diabetes Mellitus (DM) is a significant global health concern, with Type 2 DM (T2DM) being highly prevalent. Glucagon-Like Peptide 1 receptor agonists (GLP-1RA), such as Danuglipron, offer potential benefits in T2DM management. This meta-analysis examines the safety and efficacy of Danuglipron, focusing on adverse outcomes and glycemic parameters. Methods: A systematic search was conducted in PubMed, Scopus, and Cochrane Library for RCTs involving Danuglipron till August 2023, following PRISMA guidelines. The Cochrane risk-of-bias tool was used for quality assessment. Adverse outcomes (diarrhea, nausea, vomiting, headache, decreased appetite, dyspepsia, dizziness) and glycemic parameters like changes in HbA1C, fasting plasma glucose (FPG), and body weight were analyzed. Results: Four RCTs published from 2021 to 2023 were included. Both doses of Danuglipron were associated with diarrhea (RR=2.66, 90% CI: 1.32 to 5.35, p=0.02), nausea (RR=5.5, 90% CI: 3.4 to 8.88, p< 0.00001), and vomiting (RR=5.98, 90% CI: 2.93 to 12.23, p=0.0001). The 120mg dose showed decreased appetite (RR=3.46, 90% CI: 1.57 to 7.62, p=0.01), dyspepsia (RR=4.04, 90% CI: 1.93 to 8.43, p=0.002), and dizziness (RR=5.08, 90% CI: 1.45 to 17.82, p=0.03). Reductions in HbA1C (SMD − 1.09, 90% CI − 1.39 to − 0.8, p < 0.00001), FPG (SMD − 1.10, 90% CI − 1.46 to − 0.75, p < 0.00001), and body weight (SMD − 1.08, 90% CI − 1.42 to − 0.74, p < 0.00001) were observed for both doses. Conclusion: Danuglipron demonstrates potential for glycemic control and weight reduction in T2DM. Adverse outcomes include diarrhea, nausea, vomiting, and decreased appetite, with dose-related effects. Clinicians must weigh benefits against side effects when considering Danuglipron for T2DM management.

21 August 2023 in Annals of Neurosciences
Verified
Journal Article
Open access
HFHareer Fatima
Hareer Fatima
HRHussain Sohail Rangwala
Hussain Sohail Rangwala
FRFaiza Riaz
Faiza Riaz
BRBurhanuddin Sohail Rangwala
Burhanuddin Sohail Rangwala
MSMohammad Arham Siddiq
Mohammad Arham Siddiq
Background: Alzheimer’s disease (AD) is a widespread neurodegenerative disorder with a significant global impact, affecting approximately 50 million individuals, and projections estimate that up to 152 million people will be affected by 2050. AD is characterized by beta-amyloid plaques and tau tangles in the brain, leading to cognitive decline. Summary: Recent research on AD has made significant strides, including the development of an “amyloid clock” biomarker that tracks AD progression through positron emission tomography (PET) scans. Surf4 and other genes have been discovered to play a role in regulating beta-amyloid toxicity, while inhibiting the enzyme hexokinase-2 has shown positive results in preclinical studies. New brain mapping techniques have identified early brain-based causes of cognitive changes in AD, and biomarkers such as neuronal pentraxin protein Nptx2 and astrocytic 7-subunit of the nicotinic acetylcholine receptors (7nAChRs) show potential for early detection. Other approaches, such as replenishing the enzyme Tip60, selectively degrading the modified protein p-p38 with PRZ-18002, and targeting the protein voltage-dependent anion channel-1 (VDAC1), have shown promise in enhancing cognitive function and preventing pathophysiological alterations linked to AD. Baseline blood samples and other biomarkers such as urine formic acid, p-tau 198, microRNAs, and glial fibrillary acidic protein (GFAP) have also been discovered for early detection and intervention of AD. Additionally, recent FDA approvals for medications such as aducanumab and lecanemab provide options for reducing AD symptoms and improving function, while clinical trials for dementia vaccines show promise for the nasal and beta-amyloid 40 vaccines as well as vaccinations targeting tau. Key Messages: These advancements in AD research, including biomarker discovery and the development of disease-modifying treatments, are crucial steps towards improving the lives of those affected by AD and finding a cure for this debilitating disease.

1 July 2023 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
MSMuhammad Ashir Shafique
Muhammad Ashir Shafique
AHAbdul Haseeb
Abdul Haseeb
MSMohammad Arham Siddiq
Mohammad Arham Siddiq
AMAbdullah Mussarat
Abdullah Mussarat
HRHussain Sohail Rangwala
Hussain Sohail Rangwala
MMMuhammad Saqlain Mustafa
Muhammad Saqlain Mustafa
Urothelial carcinoma is a common malignancy that affects the urinary system, with bladder cancer being the most prevalent form. Although the management of early-stage disease has seen significant improvements, the treatment of locally advanced and metastatic urothelial carcinoma remains challenging. Over the past decade, there has been an explosion in the number of therapies available for the treatment of advanced disease, with immune checkpoint inhibitors and antibody-drug conjugates leading the way. Enfortumab vedotin is an antibody-drug conjugate that targets Nectin-4, a protein that is overexpressed in urothelial carcinoma cells. In clinical trials, it has shown promising outcomes for the treatment of advanced urothelial carcinoma that has progressed after chemotherapy or immunotherapy. The US Food and Drug Administration has granted expedited approval for enfortumab vedotin in the treatment of advanced urothelial carcinoma. This review provides an overview of the current and emerging treatments for urothelial carcinoma, with a particular focus on enfortumab vedotin. We discuss the mechanisms of action, clinical efficacy, safety, and ongoing research of enfortumab vedotin, along with the current landscape of other approved therapies and promising agents in development. The aim of this review is to provide a comprehensive and up-to-date summary of the available treatment options for urothelial carcinoma, including their limitations and future prospects.

13 December 2023 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
SASyed Muhammad Sinaan Ali
Syed Muhammad Sinaan Ali
MSMuhammad Ashir Shafique
Muhammad Ashir Shafique
MMMuhammad Saqlain Mustafa
Muhammad Saqlain Mustafa
SJSyed Ahsan Ali Jafri
Syed Ahsan Ali Jafri
SKSara Khalil
Sara Khalil
HRHussain Sohail Rangwala
Hussain Sohail Rangwala

25 March 2024 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
HRHussain Sohail Rangwala
Hussain Sohail Rangwala
HFHareer Fatima
Hareer Fatima
MAMirha Ali
Mirha Ali
MMMuhammad Saqlain Mustafa
Muhammad Saqlain Mustafa
MSMuhammad Ashir Shafique
Muhammad Ashir Shafique
SASyed Raza Abbas
Syed Raza Abbas